Clinical Trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-10-15; most recent amendment 2026-03-23.
Status change: Recruiting → Active, Not Recruiting 2026-03-23
Trial Details
NCT Number NCT06645886
Lead Sponsor Kumquat Biosciences Inc.
Conditions Hematologic Malignancies, Adult
Enrollment 13 participants
Start Date 2024-12-09
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-25